MENU
+Compare
REPL
Stock ticker: NASDAQ
AS OF
Dec 3, 04:59 PM (EDT)
Price
$10.31
Change
+$0.31 (+3.10%)
Capitalization
761.68M

REPL Replimune Group Forecast, Technical & Fundamental Analysis

Replimune Group Inc is a clinical-stage biotechnology company... Show more

Industry: #Biotechnology
REPL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for REPL with price predictions
Nov 28, 2025

REPL's RSI Indicator is remaining in overbought zone for 1 day

Watch for a price pull-back in the near future.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Moving Average Convergence Divergence Histogram (MACD) for REPL turned negative on November 06, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where REPL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

REPL broke above its upper Bollinger Band on November 26, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 19, 2025. You may want to consider a long position or call options on REPL as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in of 257 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 178 cases where REPL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.893) is normal, around the industry mean (27.312). P/E Ratio (0.000) is within average values for comparable stocks, (52.442). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.886). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (321.020).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
REPL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

REPL is expected to report earnings to fall 15.01% to -76 cents per share on February 11

Replimune Group REPL Stock Earnings Reports
Q4'25
Est.
$-0.76
Q3'25
Missed
by $0.13
Q2'25
Missed
by $0.11
Q1'25
Missed
by $2.35
Q4'24
Missed
by $0.03
The last earnings report on November 06 showed earnings per share of -89 cents, missing the estimate of -77 cents. With 812.34K shares outstanding, the current market capitalization sits at 761.68M.
A.I. Advisor
published General Information

General Information

a developer of oncolytic immunotherapies

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
500 Unicorn Park Drive
Phone
+1 781 222-9600
Employees
284
Web
https://www.replimune.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PGWAX103.82N/A
N/A
Virtus Silvant Focused Growth A
AGSCX6.91N/A
N/A
Alger Small Cap Growth C
CLTCX16.74N/A
N/A
Catalyst/Lyons Tactical Allocation C
GHAYX49.68N/A
N/A
VanEck Global Resources Fund Y
HGOFX76.86N/A
N/A
Hartford Growth Opportunities F

REPL and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with NEVPF. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
+3.19%
NEVPF - REPL
64%
Loosely correlated
N/A
ELVAF - REPL
60%
Loosely correlated
N/A
IMNN - REPL
57%
Loosely correlated
+0.76%
SNDX - REPL
49%
Loosely correlated
-1.67%
KYMR - REPL
45%
Loosely correlated
-3.80%
More